(1R,2S)-1-Ethylamino-indan-2-ol | 477284-48-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: (1R,2S)-1-Ethylamino-indan-2-ol
• 英文别名: (1R,2S)-1-(ethylamino)-2,3-dihydro-1H-inden-2-ol
• CAS: 477284-48-3
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: PAHYHBDTHMJCLS-WDEREUQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  三甲基环三硼氧烷 、 (1R,2S)-1-Ethylamino-indan-2-ol 以 甲苯 为溶剂， 生成 (3aR,8aS)-3-Ethyl-2-methyl-3,3a,8,8a-tetrahydro-2H-1-oxa-3-aza-2-bora-cyclopenta[a]indene
  参考文献：
  名称：

  Efficient desymmetrisation of a meso-imide using a chiral oxazaborolidine catalyst

  摘要：

  Desymmetrisation of a meso-imide by enantioselective reduction using a chiral oxazaborolidine catalyst derived from (1R,2S)-cis-1-amino-2-indanol followed by reduction of the hydroxylactam product proceeded with good enantiomeric excess (80-91%) at significantly lower catalyst loadings compared to reactions using the prolinol-derived catalyst. Models for the selectivity observed are proposed based upon structural probes and experimental observations. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(02)00248-3
• 作为产物：
  描述：

  (1R,2S)-1-氨基-2-茚醇 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 20.0h， 生成 (1R,2S)-1-Ethylamino-indan-2-ol
  参考文献：
  名称：

  Efficient desymmetrisation of a meso-imide using a chiral oxazaborolidine catalyst

  摘要：

  Desymmetrisation of a meso-imide by enantioselective reduction using a chiral oxazaborolidine catalyst derived from (1R,2S)-cis-1-amino-2-indanol followed by reduction of the hydroxylactam product proceeded with good enantiomeric excess (80-91%) at significantly lower catalyst loadings compared to reactions using the prolinol-derived catalyst. Models for the selectivity observed are proposed based upon structural probes and experimental observations. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(02)00248-3

文献信息

• Cannabinoid receptor ligands and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040214837A1

  公开（公告）日：2004-10-28

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
• Benzene, Pyridine, and Pyridazine Derivatives
  申请人：Huang Kenneth He

  公开号：US20080096887A1

  公开（公告）日：2008-04-24

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, Q 1 , Q 2 , Q 3 , Y, and X 1 -X 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明公开了式I的化合物和药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、n、Q1、Q2、Q3、Y和X1-X4的定义如本文所述。式I的化合物可用于治疗与细胞增殖有关的疾病和/或疾病，例如癌症、炎症、关节炎、血管生成或类似疾病。本发明还公开了包含本发明化合物的制药组合物和使用这些化合物治疗上述疾病的方法。
• CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
  申请人：Griffith A. David

  公开号：US20070275964A1

  公开（公告）日：2007-11-29

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

  本文描述了化学式为(I)的化合物，它们作为大麻素受体配体并在动物中治疗与大麻素受体介导相关的疾病中的用途。
• BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES
  申请人：Huang Kenneth He

  公开号：US20110034529A1

  公开（公告）日：2011-02-10

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, Q 1 , Q 2 , Q 3 , Y, and X 1 -X 4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明公开了I式化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、n、Q1、Q2、Q3、Y和X1-X4如所定义。I式化合物在治疗与细胞增殖相关的疾病和/或病情，如癌症、炎症、关节炎、血管生成等方面具有用途。本发明还公开了包含本发明化合物的药物组合物及使用这些化合物治疗上述疾病的方法。
• Tetrahydroindolone and tetrahydroindazolone derivatives
  申请人：Esanex, Inc.

  公开号：EP2380879B1

  公开（公告）日：2017-07-12